|
1
|
Platzbecker U, Kubasch AS,
Homer-Bouthiette C and Prebet T: Current challenges and unmet
medical needs in myelodysplastic syndromes. Leukemia. 35:2182–2198.
2021. View Article : Google Scholar
|
|
2
|
Adès L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar
|
|
3
|
Raaijmakers MH: Myelodysplastic syndromes:
Revisiting the role of the bone marrow microenvironment in disease
pathogenesis. Int J Hematol. 95:17–25. 2012. View Article : Google Scholar
|
|
4
|
Ishibashi M, Tamura H and Ogata K: Disease
progression mechanism in myelodysplastic syndromes: Insight into
the role of the microenvironment. Leuk Res. 35:1449–1452. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medyouf H, Mossner M, Jann JC, Nolte F,
Raffel S, Herrmann C, Lier A, Eisen C, Nowak V, Zens B, et al:
Myelodysplastic cells in patients reprogram mesenchymal stromal
cells to establish a transplantable stem cell niche disease unit.
Cell Stem Cell. 14:824–837. 2014. View Article : Google Scholar
|
|
6
|
Balderman SR, Li AJ, Hoffman CM, Frisch
BJ, Goodman AN, LaMere MW, Georger MA, Evans AG, Liesveld JL,
Becker MW and Calvi LM: Targeting of the bone marrow
microenvironment improves outcome in a murine model of
myelodysplastic syndrome. Blood. 127:616–625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raaijmakers MH, Mukherjee S, Guo S, Zhang
S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian
RP, Scadden EO, et al: Bone progenitor dysfunction induces
myelodysplasia and secondary leukaemia. Nature. 464:852–857. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roela RA, Carraro DM, Brentani HP, Kaiano
JH, Simão DF, Guarnieiro R, Lopes LF, Borojevic R and Brentani MM:
Gene stage-specific expression in the microenvironment of pediatric
myelodysplastic syndromes. Leuk Res. 31:579–589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Corradi G, Baldazzi C, Očadlíková D,
Marconi G, Parisi S, Testoni N, Finelli C, Cavo M, Curti A and
Ciciarello M: Mesenchymal stromal cells from myelodysplastic and
acute myeloid leukemia patients display in vitro reduced
proliferative potential and similar capacity to suppotr leukemia
cell survival. Stem Cell Res Ther. 9:2712018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Frolova O, Samudio I, Benito JM, Jacamo R,
Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, et al:
Regulation of HIF-1α signaling and chemoresistance in acute
lymphocytic leukemia under hypoxic conditions of the bone marrow
microenvironment. Cancer Biol Ther. 13:858–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Albadari N, Deng S and Li W: The
transcriptional factors HIF-1 and HIF-2 and their novel inhibitors
in cancer therapy. Expert Opin Drug Discov. 14:667–682. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Minami T, Matsumura N, Sugimoto K, Shimizu
N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M and
Uemura H: Hypoxia-inducing factor (HIF)-1α-derived peptide capable
of inducing cancer-reactive cytotoxic T lymphocytes from
HLA-A24+ patients with renal cell carcinoma. Int
Immunopharmacol. 44:197–202. 2017. View Article : Google Scholar
|
|
13
|
Lotfinia M, Lak S, Mohammadi Ghahhari N,
Johari B, Maghsood F, Parsania S, Sadegh Tabrizi B and Kadivar M:
Hypoxia Pre-Conditioned embryonic mesenchymal stem cell secretome
reduces IL-10 production by peripheral blood mononuclear cells.
Iran Biomed J. 21:24–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayashi Y, Zhang Y, Yokota A, Yan X, Liu
J, Choi K, Li B, Sashida G, Peng Y, Xu Z, et al: Pathobiological
pseudohypoxia as a putative mechanism underlying myelodysplastic
syndromes. Cancer Discov. 8:1438–1457. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hayashi Y: Role of HIF1A in the
development of myelodysplastic syndromes. Rinsho Ketsueki.
60:818–823. 2019.(In Japanese).
|
|
16
|
Ma CP, Liu H, Yi-Feng Chang I, Wang WC,
Chen YT, Wu SM, Chen HW, Kuo YP, Shih CT, Li CY and Tan BC: ADAR1
promotes robust hypoxia signaling via distinct regulation of
multiple HIF-1α-inhibiting factors. EMBO Rep. 20:e471072019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JH, Yoon YM and Lee SH: Hypoxic
preconditioning promotes the bioactivities of mesenchymal stem
cells via the HIF-1α-GRP78-Akt Axis. Int J Mol Sci. 18:13202017.
View Article : Google Scholar
|
|
18
|
Chen T, Zhu H, Wang Y, Zhao P, Chen J, Sun
J, Zhang X and Zhu G: Apoptosis of bone marrow mesenchymal
stromal/stem cells via the MAPK and endoplasmic reticulum stress
signaling pathways. Am J Transl Res. 10:2555–2566. 2018.PubMed/NCBI
|
|
19
|
Benton CB, Khan M, Sallman D, Nazha A,
Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E,
et al: Prognosis of patients with intermediate risk IPSS-R
myelodysplastic syndrome indicates variable outcomes and need for
models beyond IPSS-R. Am J Hematol. 93:1245–1253. 2018. View Article : Google Scholar
|
|
20
|
Garcia-Manero G: Myelodysplasic syndromes:
2011 update on diagnosis, risk-stratification, and management. Am J
Hematol. 86:490–498. 2011. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Flores-Figueroa E, Varma S, Montgomery K,
Greenberg PL and Gratzinger D: Distinctive contact between
CD34+ hematopoietic progenitors and CXCL12+
CD271+ mesenchymal stromal cells in benign and
myelodysplastic bone marrow. Lab Invest. 92:1330–1341. 2012.
View Article : Google Scholar
|
|
23
|
Purwaningrum M, Jamilah NS, Purbantoro SD,
Sawangmake C and Nantavisai S: Comparative characteristic study
from bone marrow-derived mesenchymal stem cells. J Vet Sci.
22:e742021. View Article : Google Scholar
|
|
24
|
Busser H, Najar M, Raicevic G, Pieters K,
Velez Pombo R, Philippart P, Meuleman N, Bron D and Lagneaux L:
Isolation and characterization of human mesenchymal stromal cells
subpopulations: Comparison of bone marrow and adipose tissue. Stem
Cells Dev. 24:2142–2157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dominici M, Le Blanc K, Mueller I,
Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A,
Prockop Dj and Horwitz E: Minimal criteria for defining multipotent
mesenchymal stromal cells. The International society for cellular
therapy position statement. Cytotherapy. 8:315–317. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cicione C, Muiños-López E, Hermida-Gómez
T, Fuentes-Boquete I, Díaz-Prado S and Blanco FJ: Effects of severe
hypoxia on bone marrow mesenchymal stem cells differentiation
potential. Stem Cells Int. 2013:2328962013. View Article : Google Scholar
|
|
27
|
Guang FR, Ling Z, Huang JS, Huang WX, Gong
BD, Fang XX, Zhang XY and Tang JP: Effect of mesenchymal stem cells
on Sjögren-like mice and the microRNA expression profiles of
splenic CD4+ T cells. Exp Ther Med. 13:2828–2838. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johnson RC, Kurzer JH, Greenberg PL and
Gratzinger D: Mesenchymal stromal cell density is increased in
higher grade myelodysplastic syndromes and independently predicts
survival. Am J Clin Pathol. 142:795–802. 2014. View Article : Google Scholar
|
|
29
|
Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S,
Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat
F, et al: Eprenetapopt plus azacitidine in TP53-mutated
myelodysplastic syndromes and acute myeloid leukemia: A phase II
Study by the Groupe Francophone des Myelodysplasies (GFM). J Clin
Oncol. 39:1575–1583. 2021. View Article : Google Scholar
|
|
30
|
Gars E, Yousry SM, Babu D, Kurzer JH,
George TI and Gratzinger D: A replicable CD271+
mesenchymal stromal cell density score: Bringing the dysfunctional
myelodysplastic syndrome niche to the diagnostic laboratory. Leuk
Lymphoma. 58:1730–1732. 2017. View Article : Google Scholar
|
|
31
|
Ohnishi S, Yasuda T, Kitamura S and Nagaya
N: Effect of hypoxia on gene expression of bone marrow-derived
mesenchymal stem cells and mononuclear cells. Stem Cells.
25:1166–1177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Elshabrawy HA, Chen Z, Volin MV, Ravella
S, Virupannavar S and Shahrara S: The pathogenic role of
angiogenesis in rheumatoid arthritis. Angiogenesis. 18:433–448.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alonso D, Serrano E, Bermejo FJ and Corral
RS: HIF-1α-regulated MIF activation and Nox2-dependent ROS
generation promote Leishmania amazonensis killing by macrophages
under hypoxia. Cell Immunol. 335:15–21. 2019. View Article : Google Scholar
|
|
34
|
Abdul-Aziz AM, Shafat MS, Mehta TK, Di
Palma F, Lawes MJ, Rushworth SA and Bowles KM: MIF-Induced Stromal
PKCβ/IL8 is essential in human acute myeloid Leukemia. Cancer Res.
77:303–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mangano K, Mazzon E, Basile MS, Di Marco
R, Bramanti P, Mammana S, Petralia MC, Fagone P and Nicoletti F:
Pathogenic role for macrophage migration inhibitory factor in
glioblastoma and its targeting with specific inhibitors as novel
tailored therapeutic approach. Oncotarget. 9:17951–17970. 2018.
View Article : Google Scholar
|
|
36
|
Xu S, Guo X, Gao X, Xue H, Zhang J, Guo X,
Qiu W, Zhang P and Li G: Macrophage migration inhibitory factor
enhances autophagy by regulating ROCK1 activity and contributes to
the escape of dendritic cell surveillance in glioblastoma. Int J
Oncol. 49:2105–2115. 2016. View Article : Google Scholar
|
|
37
|
Presti M, Mazzon E, Basile MS, Petralia
MC, Bramanti A, Colletti G, Bramanti P, Nicoletti F and Fagone P:
Overexpression of macrophage migration inhibitory factor and
functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in
glioblastoma. Oncol Lett. 16:2881–2886. 2018.
|
|
38
|
Cavalli E, Ciurleo R, Petralia MC, Fagone
P, Bella R, Mangano K, Nicoletti F, Bramanti P and Basile MS:
Emerging role of the macrophage migration inhibitory factor family
of cytokines in neuroblastoma. Pathogenic effectors and novel
therapeutic targets? Molecules. 25:11942020.
|
|
39
|
Soumoy L, Kindt N, Ghanem G, Saussez S and
Journe F: Role of macrophage migration inhibitory factor (MIF) in
melanoma. Cancers (Basel). 11:5292019. View Article : Google Scholar
|
|
40
|
Falantes JF, Trujillo P, Piruat JI,
Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez
M, González J, Martino ML, et al: Overexpression of GYS1, MIF, and
MYC is associated with adverse outcome and poor response to
azacitidine in myelodysplastic syndromes and acute myeloid
leukemia. Clin Lymphoma Myeloma Leuk. 15:236–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stergiou IE, Kambas K, Poulaki A,
Giannouli S, Katsila T, Dimitrakopoulou A, Vidali V, Mouchtouris V,
Kloukina I, Xingi E, et al: Exploiting the role of
hypoxia-inducible factor 1 and pseudohypoxia in the myelodysplastic
syndrome pathophysiology. Int J Mol Sci. 22:40992021. View Article : Google Scholar
|
|
42
|
Tong H, Hu C, Zhuang Z, Wang L and Jin J:
Hypoxia-inducible factor-1α expression indicates poor prognosis in
myelodysplastic syndromes. Leuk Lymphoma. 53:2412–2418. 2012.
View Article : Google Scholar
|
|
43
|
Liu Z, Tian M, Ding K, Liu H, Wang Y and
Fu R: High expression of PIM2 induces HSC proliferation in
myelodysplastic syndromes via the IDH1/HIF1-α signaling pathway.
Oncol Lett. 17:5395–5402. 2019.
|
|
44
|
Pleyer L, Valent P and Greil R:
Mesenchymal stem and progenitor cells in normal and dysplastic
hematopoiesis-masters of survival and clonality? Int J Mol Sci.
17:10092016. View Article : Google Scholar
|
|
45
|
Blau O, Baldus CD, Hofmann WK, Thiel G,
Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram
A, et al: Mesenchymal stromal cells of myelodysplastic syndrome and
acute myeloid leukemia patients have distinct genetic abnormalities
compared with leukemic blasts. Blood. 118:5583–5592. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang H, Niu H, Zhang T, Xing L, Shao Z and
Fu R: Low- and intermediate-risk myelodysplastic syndrome with pure
red cell aplasia. Hematology. 26:444–446. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sato F, Miyaoka Y, Miyajima A and Tanaka
M: Oncostatin M maintains the hematopoietic microenvironment in the
bone marrow by modulating adipogenesis and osteogenesis. PLoS One.
9:e1162092014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tehranchi R, Fadeel B, Forsblom AM,
Christensson B, Samuelsson J, Zhivotovsky B and Hellstrom-Lindberg
E: Granulocyte colony-stimulating factor inhibits spontaneous
cytochrome C release and mitochondria-dependent apoptosis of
myelodysplastic syndrome hematopoietic progenitors. Blood.
101:1080–1086. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ferrer RA, Wobus M, List C, Wehner R,
Schönefeldt C, Brocard B, Mohr B, Rauner M, Schmitz M, Stiehler M,
et al: Mesenchymal stromal cells from patients with myelodyplastic
syndrome display distinct functional alterations that are modulated
by lenalidomide. Haematologica. 98:1677–1685. 2013. View Article : Google Scholar
|
|
50
|
Bakhtiari T, Ghaderi A, Safaee Nodehi SR,
Aghazadeh Z, Tofighi Zavareh F, Jafarnezhad-Ansariha F, Barati A
and Mirshafiey A: An in vitro assessment for evaluating the
efficiency of β-d-mannuronic acid (M2000) in myelodysplastic
syndrome. J Cell Physiol. 234:12971–12977. 2019. View Article : Google Scholar
|
|
51
|
da Silva-Coelho P, Kroeze LI, Yoshida K,
Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop
M, Sandmann S, Dugas M, et al: Clonal evolution in myelodysplastic
syndromes. Nat Commun. 8:150992017. View Article : Google Scholar : PubMed/NCBI
|
